Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

516
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
516
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

295
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
295
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

358
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
358
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

647
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
647
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

433
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
433

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Gradient-Guided Graph Contrastive Learning for Mass Spectrometry-Based Proteomics Clustering.

Journal of chemical information and modeling·2026
Same author

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same author

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same author

Cardiorenal Syndrome and Depressive Symptoms: Exploring the Mood-Kidney Link With Heart Failure Risk in a Post-hoc Analysis of SPRINT.

Kidney medicine·2026
Same author

A comprehensive review on chemical structure, quality control, pharmacological effects, and structure-activity relationship of saponins from Zhuzishen ().

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026
Same author

Clinical Characteristics and Long-Term Outcomes of Patients With Fibrosing Mediastinitis: A Multicenter Retrospective Cohort Study.

JACC. Asia·2026

相关实验视频

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

临床表现 临床表现

Amara Sarwal1, Ravinder Singh1, Guo Wei1

  • 1University of Utah, Salt Lake City, UT, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括

在2型糖尿病患者中,利拉格卢提德的使用与阿尔茨海默病和痴呆症的风险较低,与塞马格卢提德相比. 利拉格卢提德还表明,与其他类似葡萄糖素的-1受体激动剂相比,死亡风险降低.

更多相关视频

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

相关实验视频

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

科学领域:

  • 内分泌学 在内分泌学.
  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 类似葡萄糖类-1受体激动剂 (GLP-1RA),如利拉格卢提德,塞马格卢提德和杜拉格卢提德,是2型糖尿病 (T2D) 管理的关键.
  • 新出现的证据表明,GLP-1RA的使用可能会降低痴呆风险,但类内差异需要调查.

研究的目的:

  • 为了比较患有阿尔茨海默氏症和相关痴呆症 (AD/ADRD) 的风险,T2D患者开始服用利拉格胺,半胺或杜拉格胺.
  • 评估这些GLP-1RA与死亡风险之间的关联.

主要方法:

  • 一项活跃的对比,新用户设计研究包括21,173名T2D退伍军人开始服用利拉格卢提德,西马格卢提德或杜拉格卢提德.
  • 一般化倾向得分反向概率加权 (IPW) 控制混.
  • IPW 考克斯模型评估了AD/ADRD,死亡和复合结局的风险.

主要成果:

  • 利拉格卢提德与塞马格卢提德相比,AD/ADRD的风险较低 (HR 0.68),与杜拉格卢提德的风险相似.
  • 与杜拉格卢提德相比,塞马格卢提德的AD/ADRD风险更高 (HR 1.32).
  • 利拉格卢提德与所有死因的最低风险和复合AD/ADRD/死亡结局有关.

结论:

  • 利拉格卢提德与塞马格卢提德相比,AD/ADRD的风险降低,死亡风险低于其他研究的GLP-1RA.
  • 杜拉古类药物与利拉古类药物具有类似的AD/ADRD风险,但没有显著的死亡率益处.